149 related articles for article (PubMed ID: 33810240)
21. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
22. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
23. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
26. Everolimus selectively targets vemurafenib resistant BRAF
Ruzzolini J; Peppicelli S; Andreucci E; Bianchini F; Margheri F; Laurenzana A; Fibbi G; Pimpinelli N; Calorini L
Cancer Lett; 2017 Nov; 408():43-54. PubMed ID: 28826720
[TBL] [Abstract][Full Text] [Related]
27. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
Spain L; Julve M; Larkin J
Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150
[TBL] [Abstract][Full Text] [Related]
28. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
29. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
32. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
33. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
34. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
[TBL] [Abstract][Full Text] [Related]
37. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
38. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]